Journal of ethnicity in substance abuse
April 22, 2026
Naseem Abdulmohi Alhujaili, O. Ayonrinde
Cannabis use has long been linked to the emergence and worsening of psychotic disorders, particularly among adolescents and young adults. This study aimed to determine the prevalence of cannabis use and its psychiatric associations in youth and young adults enrolled in an Early Psychosis Intervention (EPI) program in Southeast Ontario. A retrospective cross-sectional analysis was conducted on...
Cancer causes & control : CCC
April 22, 2026
Amrit Baral, Yue Pan, Wayway M. Hlaing et al.
To examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors. We analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n =...
Behavioral Sciences
April 20, 2026
Jeffrey Alan Gibbons, Chayse Angela Cotton, Matthew Traversa et al.
The fading affect bias (FAB) is the faster fading of unpleasant than pleasant affect, and this effect is positively and negatively related to healthy/adaptive and unhealthy/non-adaptive outcomes, respectively. Research has argued that the FAB makes people happy and it prompts them to seek out pleasant experiences. Although Pillersdorf and Scoboria found a negative relation between the FAB and...
American Journal of Psychiatry
April 17, 2026
Shih-Hsuan Ku, Sierra J Stringfield, Mary M Torregrossa et al.
The relationship between the endocannabinoid system and the emergence and treatment of schizophrenia-related symptoms continues to be a topic of significant interest within psychiatry. Cannabis is the most widely used recreational drug worldwide, and individuals with schizophrenia use it at a much higher rate than the general population. The shared genetic risk for schizophrenia and cannabis...
Journal of Neuroinflammation
April 17, 2026
Mary K Ford, Peter W Halcrow, Anna E Laird et al.
Chronic neuroinflammation is associated with comorbidities in people with HIV (PWH) on antiretroviral therapy (ART). While cannabis use is associated with reduced neuroinflammation and neurocognitive impairment (NCI) in PWH, the underlying mechanisms are unknown. To address this gap in knowledge, we analyzed monocyte-derived macrophages (MDMs) from a cohort of 50 PWH and 33 people without HIV...
Frontiers in Behavioral Neuroscience
April 16, 2026
Chen Hanna Ryder, Carmit Gal, Einav Levy et al.
Introduction With expanding global cannabis legalization and rising usage rates, elucidating the specific neurocognitive impact of acute cannabis intoxication across biological sexes is critical. Methods Using a 2 × 2 factorial design, we examined 154 adults: 77 individuals who use cannabis regularly (≥ 5 days/week for ≥ 1 year; 46 males, 31 females) and 77 matched controls (32 males, 45...
Psychopharmacology
April 15, 2026
Hanna Molla, Evan Hahn, Christian Ramos et al.
Abstract Rationale Many cannabis users claim that one reason they use cannabis is to relieve stress or dampen effects of stressful memories. However, the processes by which cannabis or its primary constituent, Δ 9 -tetrahydrocannabinol (THC) alleviate stressful experiences remains unclear. Objective Here, we assessed whether low oral doses of THC reduce emotional or physiological responses to...
Acta Psychiatrica Scandinavica
April 8, 2026
Antti Mustonen, Solja Niemelä, Alexander Denissoff et al.
Research indicates that first‐episode psychosis (FEP) with cannabis use disorder (CUD) carries a substantial disease burden, but more granular clinical trajectories of cannabis‐related psychoses remain unclear. This study examines the clinical trajectories of first clinically diagnosed FEP&CUD and cannabis‐induced psychosis (CIP) in comparison with FEP without substance use disorder (SUD).
Journal of Australian studies
April 3, 2026
Clare J. Burnett
ABSTRACT In 1868 eminent Australian author Marcus Clarke wrote a gothic tale for his own Colonial Monthly Magazine titled “Cannabis Indica”, purportedly under the influence of hashish. Contemporaneous reviewers discussed this little-known short story as merely a curio, and modern scholars have followed suit. However, the experimental short story is distinguished as one of the first fictional...
Cannabis and Cannabinoid Research
April 2026
Conor H. Murray, Joshua Cassarino, Ziva D. Cooper
The effect of cannabis use on health is likely to depend on individual differences. In particular, there is a growing need to understand the impact of cannabis and delta-9-tetrahydrocannabinol (THC) on brain and behavioral health across the lifespan. We conducted a narrative review summarizing the effects of cannabis and THC across three stages of life: in utero, adolescence, and late...
Drug and Alcohol Dependence
April 1, 2026
Che Liu, Janna Cousijn, Emese Kroon et al.
Although behavioral and epidemiological studies demonstrate high co-morbidity between cannabis use and depression, the underlying neurobiological mechanisms of this relationship remain poorly understood. This study evaluated the interaction between cannabis use and depression on brain resting state functional connectivity using graph theory network properties in 223 individuals who currently...
The International Journal of Neuropsychopharmacology
April 1, 2026
Mary M Torregrossa, Tamara Racic, S. Baglot et al.
Abstract Background Most substance users are polysubstance users; however, little is known about how the combined use of different drugs affects the course of substance use disorder or effectiveness of treatment. Notably, co-use of cannabis and nicotine is very common, and we previously demonstrated that nicotine enhances the self-administration of a synthetic cannabinoid receptor agonist and...
Asian Journal of Psychiatry
April 1, 2026
Valerio Ricci, Alessandro Sarni, Marialuigia Barresi et al.
BACKGROUND Cannabis-induced psychotic disorders represent 12-35% of first-episode psychosis presentations globally. Traditional clinical wisdom holds these conditions carry favorable prognosis based on rapid symptomatic improvement, yet this narrative rests almost exclusively on symptomatic outcomes, overlooking functional, cognitive, and subjective recovery dimensions. OBJECTIVE To...
Medical Imaging
April 1, 2026
A. Wismüller, A. Vosoughi, Akhil Kasturi
Functional magnetic resonance imaging (fMRI) in the resting state often involves analyzing thousands of potential connections with only a few hundred time points, presenting a significant challenge in causal modeling and topology inference of brain networks. This study evaluates whether large-scale Granger Causality (lsGC)—which uses principal component analysis and autoregressive modeling—can...
The British Journal of Psychiatry
April 1, 2026
Rashmi Patel
Summary Cannabis use increases the risk of psychosis, but cannabis-based medicinal products may provide additional therapeutic opportunities. Decriminalisation of cannabis has led to wider availability in certain jurisdictions, while in the UK regulated medicinal preparations are not readily accessible. A more balanced approach could reduce harms while maximising potential therapeutic benefits.
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
April 1, 2026
Daniel Bello, J. Connolly, Jean Addington et al.
BACKGROUND Cannabis use is highly prevalent among people with psychotic disorders. While there is some indication that cannabis use exacerbates psychosis symptoms, its neurocognitive effects remain unclear. Co-use of cannabis and tobacco is increasing in the general population, but little is known about its effects in people with psychosis or those at risk for developing a psychotic disorder,...
Drugs
April 1, 2026
Martha S. Rosenthal
This chapter examines cannabis, tracing its historical role in human history, concluding that it is one of humanity’s earliest cultivated plants. The chapter then looks at its use in medicine and rituals across ancient cultures. Globally, cannabis ranks as the most used illicit drug, with usage patterns influenced by factors such as age, gender, and geography. Legal and cultural perspectives...
Pharmacological Reports
April 1, 2026
Elmira Zolali, Mallory Burns, Sebastiano Intagliata et al.
BACKGROUND: Mu opioid receptor (MOR) agonists are the primary medication class used to treat moderate to severe pain; however, the ongoing opioid overdose crisis underscores the need for alternatives to MOR agonists for pain treatment. Delta9-tetrahydrocannabinol (THC), a cannabinoid CB1 receptor (CB1R) agonist, and sigma1 receptor (σ1R) antagonists elicit antinociceptive effects albeit less...
The journal of behavioral health services & research
April 1, 2026
Destin Rothe, Erica K Yuen, Kathleen A Moore et al.
Delta-8 THC is a psychoactive cannabinoid typically synthesized from hemp, with similar intoxicating effects as delta-9 THC. Surging public interest alongside the lack of federal regulation of delta-8 THC has led to an unclear legal landscape and increasing safety concerns. Educating young adults about the dangers of delta-8 THC is imperative. The current study investigated the effects of a...
Australasian Psychiatry
March 31, 2026
Shuichi Suetani, Faraz Honarparvar, Peter Muller et al.
Background Given that both attention-deficit hyperactivity disorder (ADHD) and cannabis use are known independent risk factors for psychosis, people with ADHD who consume cannabis may be especially vulnerable. The main objective of the current study was to explore the links between ADHD, cannabis use and psychosis outcomes. Methods A systematic review was conducted to examine the risk of...